THE NEW ARMENIAN MEDICAL JOURNAL
Volume19 (2025), Issue 3, p.23-29

DOI: https://doi.org/10.56936/18290825-3.19v.2025-23

A COMPLICATED SITUATION OF DIAGNOSIS OF BIOMARKERS IN ALCOHOLIC LIVER CIRHOSIS INJURY BY ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD

Bari Md.N.[1*], Anwar Md.[3], Ansari Md.R.[1], Osman E.H.A.[2], Alfaki, M.A.[1], Mohammad I.[1]

[1] Department of Basic Medical Sciences, College of Medicine, Prince Sattam bin Abdul-Aziz University, Al-Kharj, Saudi Arabia

[2] College of Nursing and Health Sciences, Department of Diagnostic Radiology in Jazan University Saudi Arabia

[3] College of Science, Shri Jagdishprasad Jhabarmal Tibrewala University in Jhunjhunu, India

Received 19,08.2024; Accepted for printing 15.05.2025

Abstract

Exogenous compounds, including drugs, alcohol, and herbs, can cause liver injuries that can be accurately diagnosed through laboratory testing, toxin analyses, or ultimately reactive intermediates produced during the chemical's metabolic breakdown Located the liver and capable of interacting covalently with target proteins. For idiosyncratic drug-induced liver damage Drug-induced liver injury, which is seldom diagnosed using metabolic intermediates, the circumstances are considerably different. For the diagnosis of idiosyncratic Drug-induced liver injury, the verified, liver-specific, quantitative, structured Rousseau-Uclaf Causality Assessment Method is a useful technique. Novel diagnostic biomarkers, however, are always being sought for in order to validate and supplement Rousseau Uclaf Causality Assessment Method-based Drug-induced liver injury diagnosis. With regard to peculiar Drug-induced liver injury, a subset of biomarkers—including glutamate dehydrogenase, hyper acetylated High Mobility Group Box 1, and total High Mobility Group Box 1, microRNA-122, microRNA-192, and cytokeratin analogues proteins—reached the clinical focus by adhering to prior regulatory letters of recommendations. The European Medicines Agency has recommended against using the exploratory hyper acetylated High mobility group box 1 isoform biomarkers in clinical research due to misbehavior at one of the cooperating partner sites, which has cast doubt on the validity of the novel metrics both the whole and much more the acetylated High Mobility Group Box 1. According to European Medicines Agency, the whole promise of the suggested biomarkers was heavily reliant on the remarkable outcomes of the now-indicted hyper acetylated High Mobility Group Box 1 biomarker. As a result, the European Medicines Agency made the wise decision to formally withdraw its Letter of Support, which affected each of the aforementioned biomarkers. There is currently a great deal of attention on novel biomarkers, which means that reassessments are necessary before guidelines are updated. However, Integrin beta 3 may emerge as a novel diagnostic biomarker; it has only been examined in 16 patients and may be medication specific. As a result of the significant uncertainties that still exist, it would be premature to make any definitive recommendations.

Keywords: alcoholic liver cirrhosis; biomarkers; alcoholic liver disease; diagnosis liver injury illness; roussel uclaf casualty assessment method

Cite This Article as:

Bari Md.N., Anwar Md., Ansari Md.R., Osman. E.H.A., Alfaki, M.A., Mohammad I. (2025). A complicated situation of diagnosis of biomarkers in alcoholic liver cirhosis injury by roussel uclaf causality assessment method; The New Armenian Medical Journal, vol.19 (3), 23-29; https://doi.org/10.56936/18290825-3.19v.2025-23

Address for Correspondence:

Nadeem MD Bari
Department of Basic Medical Sciences, College of Medicine, Prince Sattam bin Abdul-Aziz University, Al-Kharj, 11942, Saudi Arabia
Tel: +966509280389
E-mail: nadeembari273@gmail.com, m.bari@psau.edu.sa

Introduction

Liver cell necrosis is thought to be a major factor in the onset of liver disease. Specifically, spill-over transaminases, one of the so-called liver enzymes is frequently released into the bloodstream as a sign of liver cell necrosis [*Contreras-Zentella et al., 2016*]. because repeat biopsies are not practical for monitoring reasons. However, this strategy has proven to be inadequate in the monitoring of patients suffering from alcoholic liver disease. Transaminase levels in the blood do not accurately indicate liver cell necrosis [*Torruellas et al., 2014*].

For example, transaminase concentrations are very slightly elevated in alcoholic hepatitis, and normal levels are infrequently observed. Furthermore, elevated transaminase concentrations may, at least in part, indicate injury to other organs because they are not exclusive to the liver. It was recently proposed that γ-Guanosine triphosphate (γ-GTP) [*Tian et al., 2012*] or glutamyl trans peptidase, might serve as a helpful indicator of alcoholic liver damage elevated γ-GTP concentrations have been linked to liver cell necrosis, however in most cases, these increases are caused by non-hepatic sources, and in certain situations, elevated Concentrations could just represent alcohol-induced microsomal induction. For a variety of reasons, we concentrated on Glutamate dehydrogenasein an effort to identify a more appropriate measure of alcoholics' liver necrosis.

First off, it is mostly present in the liver, where it is concentrated (17 times higher in U/g protein) than in the heart muscle, 28 times more than in the pancreas, and 80 times higher than in skeletal muscle.8 Second, compared to the peripheral section of the liver lobule [*Sirlin et al., 2010*] Alcohol-induced liver damage typically shows up in the liver's Centro Lobular region, where its activity is 17 times greater. Thirdly, alcohol has been shown to cause mitochondrial damage, and the enzyme is only found inside mitochondria. By comparing the level. We were able to assess the usage Measuring Glutamate dehydrogenase levels in alcoholics by combining the blood enzyme value obtained on the day of the biopsy with the degree of liver cell necrosis [*Van Waes L, Lieber CS, 1977*]. The results were compared to those acquired by calculating the concentrations of conventional enzymes.

Roussel Uclaf Causality Assessment Method For Diagnisis Of Bio Marker

In order to diagnose and track liver illness and damage, laboratory testing is crucial. Viral hepatitis serologist, prothrombin time, bilirubin, aminotransferases, γ-glut amyl transferase, alkaline phosphatase, and indicators of proliferation, such as α-fetoprotein, are examples of function markers and damage markers used in liver testing today [*McGill et al., 2016*]. The most often utilized damage indicators are aspartate aminotransferases (AST) and alanine aminotransferases (ALT), respectively. On the other hand, interpreting plasma values for ALT and AST might be challenging **[***Huang et al., 2006*]. Additionally, both are not very useful as prognostic factors for acute liver damage and liver failure. The use of numerous newly identified indicators of liver damage in clinical studies has received permission from the US Food and Drug Administration and the European Medicines Agency [*Senior et al., 2014*]. Recently, the US Food and Drug Administration and the European Medicines Agency expressed approval for the use of several of the recently discovered biomarkers of liver injury in clinical trials. These biomarkers are being produced at a rapid pace. The most often utilized damage indicators are AST and ALT, respectively. On the other hand, interpreting plasma values for ALT and AST might be challenging. Additionally, both are not very useful as prognostic factors for acute liver damage and liver failure. and discuss new biomarkers for liver injury that may eventually replace or supplement ALT and AST. The powerful liver toxin known as Microcystin-leucine arginine, or Treatment of Microcystin (MC-LR), is generated by freshwater cyanobacteria, commonly referred to as blue-green algae [*Schmidt et al., 2014; Bari Md et al., 2024*]. There is currently no recognized technique for the detection and evaluation of treatment of microcystin (MC-LR) related liver injury, despite the fact that toxic algal blooms are becoming more frequent and severe globally [*Lad A, 2012*]. Prior research on healthy animals has established the standards for acceptable exposure limits to treatment of microcystin (MC-LR); nevertheless, we have shown the susceptibility to the hepatotoxic effects of Treatment of Microcystin (MC-LR) is increased in the presence of pre-existing non-alcoholic fatty liver

disease (NAFLD). The purpose of this study was to determine whether clinically used biomarkers of liver injury, namely alkaline phosphatase (ALP) and ALT in the case of pre-existing Nonalcoholic fatty liver disease (NAFLD) [*Lim A K et al., 2020*]. might be employed as diagnostic instruments for liver damage brought on by prolonged low-dose Treatment of microcystin (MC-LR) treatment.

The most prevalent and stable class of tiny Ribonucleic acid (RNAs) are called Ribonucleic acid (microRNAs), or Ribonucleic acid (mi RNAs). Though they can regulate translation, they do not encode proteins like the normal Ribonucleic acid (RNA) molecules seen in cells [*Ranganathan et al., 2014*] and as a result, it is discovered that they are crucial to the control of cellular functions. It has been demonstrated that Ribonucleic acid (miRNAs) regulate distinct genes in different ways, and during drug-induced toxicity, the expression levels of particular Ribonucleic acid (miRNAs) vary numerous times in the serum and liver [*Schofield et al., 2021*]. This review summarizes the most current findings on the biological roles of Ribonucleic acid (microRNAs) and their possible application as biomarkers for diagnosis in drug-induced liver damage. the biological functions of Ribonucleic acid(miRNA) and their potential use as diagnostic biomarkers in drug-induced liver damage **[** *Sanjay S et al., 2017; Poyil M., Bari M. 2023*].

The text on this page is taken from published literary works, which includes reviews and original research on the mechanisms behind drug-induced liver damage and the function of Ribonucleic acid (miRNA) in liver pathophysiology [*Schueller et al., 2018*]. as well as research on the possible use of Ribonucleic acid (miRNA) as a biomarker in liver damage caused by drugs. Use of Ribonucleic acid (miRNA) as a biomarker in drug-induced liver harm. Relevant material was located by searching relevant journal websites, PUBMED, Google Scholar, and other search engines [*Wang et al., 2009*].

This review does not aim to exalt aminotransferases or any other liver damage indicators. They will undoubtedly continue to be crucial instruments for the future research and diagnostics of liver damage [*Wazir et al ,2023*]. Instead, the goal aims to educate the reader about aminotransferases and discuss novel biomarkers that might someday replace or complement them. It is evident that a number of new biomarkers for liver damage perform better clinically than Alanine transaminase (ALT) and Aspartate aminotransferase (AST) in terms of early liver injury identification and outcome prediction. Before being used routinely in clinical settings, higher predictive values, however, are favored (higher NPV for patient triage and enhanced PPV for a poor prognosis in the event of liver injury) [*Bangaru et al., 2020*]. The latter may be attained, in part, by discovering completely novel indicators of liver damage or by improving the sensitivity and specificity existing multi-biomarker panels. Additionally, there is proof because certain markers, such as Glutamate dehydrogenase, mitochondrial Deoxyribonucleic acid (DNA), nuclear DNA fragments, K18, and high mobility group box 1 [*Akahashi T, 2019*]. can highlight specific pathophysiological pathways, making them useful for translational research. Ultimately, more research is required to ascertain whether any of these newly discovered indicators may be used to the forecasting unique toxicity in experimental studies.

Materials and Methods

A study was conducted on one hundred inpatient alcoholics (82 men and 18 women; daily ethanol intake: 90–180 g on average) who had liver biopsies as part of their clinical investigation. Gastritis following a binge, symptoms associated with the liver (jaundice, ascites) in 33 individuals, liver-related symptoms (jaundice, ascites) in 33 patients, issues associated with binge 54 people who had drinking (delirium tremens or began a detoxification program) [*Basra E al., 2011*] and a variety of medical conditions (hypertension, ulcer disease, malnourishment) in 9 patients. Fourteen people had clinical signs of alcoholic hepatitis, who had either no fever or a general decline in health along with weight loss, nausea, jaundice, and painful hepatomegaly. A liver biopsy was necessary in all patients if there were symptoms and physical indicators implicating the liver, increased amounts of y-globulin and bilirubin in the serum, raised transaminase levels in the serum, or both.

Blood enzyme abnormalities could not have been caused by pancreatitis, symptomatic myopathy, or overt clinical cardiac disease in any of the individuals. Thirty to four hours prior to the liver biopsy, blood was extracted for enzyme analysis

from each patient (using the Menghini or Trucut procedure). Blood enzyme levels and the patient's name were not disclosed during the blind interpretation of histology-biopsy specimens. Necrosis, fibrosis, inflammation, fat, and Mallory's hyaline were assessed in the sections Hematoxylin, eosin, and trichrome stained [*Takahashi et al., 2014*]. Thirty-four patients had cirrhosis, ten had fibrosis, and twelve had normal livers. Forty-four patients had fatty livers without parenchymal fibrosis. Every patient with cirrhosis and fibrosis also exhibited some infiltration of fat. In 18, typical Mallory corpses were found. The following was used to evaluate the degree of necrosis: 0: no necrosis or infection of the parenchyma; 1: occasionally occurring cell discontinuity, frequently indicated through an inflammatory reaction, typically of a mononuclear type 2: dispersed necrotic cell foci in the parenchyma, predominantly in the Centro lobular region ("mild alcoholic hepatitis"), with polymorph nuclear infiltration; 3. "Frank alcoholic hepatitis" is defined as widespread parenchymal necrosis with polymorph nuclear infiltrates. The biopsy specimens were independently read by 1509 hospital pathologists agreed well with our diagnoses in that the majority of patients with grades 2 and 3 were diagnosed with alcoholic hepatitis, but that diagnosis was not given to any of the patients with grade 1 necrosis. The serum-plasma was separated right away, and the samples that had been haemolysed were thrown away. Samples were kept between one and five days following collection at a temperature of -18°C until analysis. The following enzymes were measured in triplicate using normal laboratory methods at 37°C: ornithine carbamoyl transferase 14, which was measured in only 86 out of 100 patients; γ-Guanosine triphosphate, Glutamate dehydrogenase, the Serum Glutamic-Oxaloacetic Transaminase Test, Serum Glutamate Pyruvate Transaminase, Serum Glutamic-Oxaloacetic Transaminase Test, Serum Glutamate Pyruvate Transaminase , and Integrin beta-3. This brief storage time had no effect on the γ-GTP, ornithine carbamoyl transferase, or Glutamate dehydrogenase activities the activity of γ-GTP, ornithine carbamoyl transferase, or Glutamate dehydrogenase, and the highest reduction transaminase activity was eighty percent of its starting point. Every batch was tested using enzyme control samples (Sigma enzyme control 2N and 2E) for both normal and high enzyme concentrations. transaminase as well as γ-GTP tests. Only results that were within 10% of the manufacturer's stated values were considered acceptable. We produced a serum pool and utilized it as the Glutamate dehydrogenase and ornithine carbamoyl transferase control. Thirty controls were utilized in the study: twelve healthy laboratory workers and eighteen non-alcoholic patients with normal routine laboratory test results and no evidence of pancreatic, cardiac, or muscle wasting, nor clinical symptoms of liver disease [*Torruellas et al.,2014*].

Results

Evaluation of fibrosis using Transient Elastography in conjunction with ultrasonography and alcohol cessation

The figure provides a common understanding of liver stiffness in the event that laboratory and ultrasound tests are available. Following the normal blood tests and abdominal ultrasound, transient elastography is carried out immediately should the patient raise suspicions about adrenoleukodystrophy narrative as well as clinical and/or laboratory symptoms. To stabilize hemodynamics, it is recommended that patients be kept in a horizontal position for at least five minutes. The ultrasound measures the following: ascites presence, liver and spleen sizes, morphology, anomalies such congestion and cholestasis, morphological evidence of cirrhosis, and reduced caval vein diameter. After that, tansient



Figure. *Influence of AST elevation on liver stiffness measurement in adrenoleukodystrophy patients in fibrosis stages (F0–4), where F0-2 is low stage and F3-4 are advanced stages [Mueller S et al., 2015]*

elastography is carried out with the M probe or the XL probe in situations when the M probe fails, there is evident obesity, or there is ascites.

Ascites is not a contraindication for the XL probe, as it functions effectively in these situations. It is advised that individuals with increased liver stiffness and AST levels more than 100 U/ml undergo alcohol abstinence for a minimum of two weeks before having another liver stiffness assessment. The diagnosis of cirrhosis is established in individuals with liver stiffness >30 kPa, regardless of the elevated aminotransferase levels indicative of steatohepatitis. Ascites development is quite likely at these levels.

In around 95% of patients, this method allows for a conclusive non-invasive evaluation of the stage of fibrosis. Compared to normal regular ultrasonography, transient elastography can identify has a lesser number of individuals with advanced fibrosis/cirrhosis and twice as many sampling error (3–5% vs. 20–50%) [*Mueller S et al.,, 2015*]. More than one thousand seemingly healthy adults over 45 participated in a recent French electrography screening research. Of these, 7.5% showed a pathologically elevated hepatic stiffness greater than 8 *kPa*, this was eventually connected to adrenoleukodystrophy in 36 percent of the patients. Consequently, these innovative non-invasive screening methods are expected to enhance the early identification and monitoring of individuals with adrenoleukodystrophy, the most prevalent yet tragically underappreciated liver disease.

There is disagreement about whether additionally one should, for example, employ (AST)-adapted cut-off values when making ad hoc judgments for patients who do not have the time or choice to abstain from alcohol. Assessment of fibrosis with transient elastography utilizing cut-off values adjusted for inflammation recently, we created an algorithm to prevent individuals with high AST levels and Adrenoleukodystrophy from having their liver stiffness evaluated again and over. In this multicenter study, In more than 2,000 biopsy-verified patients with Adrenoleukodystrophy and Hepatitis C Virus (HCV), the cut-off values for fibrosis increased exponentially with median AST level. Although AST-adjusted threshold values prevent overestimation of fibrosis phases and provide a prompt evaluation of the fibrosis stage, even in individuals with extremely severe steatohepatitis assessment of fibrosis stage, even in patients with severe steatohepatitis, the reason for the high correlation between Aspartate aminotransferase (AST) and liver stiffness is still unknown. Furthermore, myocytes and erythrocytes may potentially be the source of AST in addition to hepatocytes. The question of whether patients with increased AST levels will inevitably experience elevated liver stiffness remains unanswered. Given that liver stiffness encompasses every pathological feature, including inflammation, ballooning, and fibrosis, drinking habits and the progression of adrenoleukodystrophy can be monitored in patients who have had an adrenoleukodystrophy measurement through transient elastography follow-up. It has been demonstrated that liver stiffness improves in over 80% of individuals soon after alcohol abstinence. Forty unpublished preliminary mortality statistics from a Heidelberg research spanning ten years demonstrate the validity of liver stiffness as a predictor of death, irrespective of both bilirubin and the international normalized ratio. Comparing different electrographic methods numerous investigations have been carried out to assess the efficacy of transient elastography directly using acoustic radiation force impulse or Shear Wave Electrography; however, reliable data about adrenoleukodystrophy are still lacking. For both long-term B and C hepatitis.

Liver transplantation

One common therapy for severe adrenoleukodystrophy is orthotropic liver transplantation. Following orthotopic liver transplantation, the patients' survival was associated with both new cancers and cardiovascular disease. This correlation clearly indicates that the transplant recipients smoke regularly. Orthotopic liver transplantation patients should keep an eye on the relationship between pre- and post-surgery mortality and cigarette smoking. According to earlier research [*Li et al., 2017*]. Occupational therapy can be a useful therapy for individuals with adrenoleukodystrophy who have significant impairments to their normal liver function. In order to prevent problems, patients undergoing orthotopic liver transplantation must also be provided with the right dietary habits and lifetime follow-up. Patients who drink alcohol for an extended period of time may have sev-

eral systemic consequences and related disorders, including myopathy, malnourishment, vitamin shortages, muscular atrophy, and neurological abnormalities [***Noble et al.,2014***]**.** Multidisciplinary therapy is ideal for people with persistent alcohol consumption, as indicated by clinical research and patient experiences.

Conclusion

Patients who may have suffered liver damage from exogenous substrates like alcohol, drugs, or phytochemicals need to undergo a comprehensive clinical examination with stringent diagnostic guidelines. Additional biomarker results supporting the diagnosis are inconsistent and sometimes disputed. For intrinsic liver impairment caused by intoxication acetaminophen and phytochemical PAs, robust biomarker data are available. A number of biomarkers for the uncommon idiosyncratic drug-induced liver injury that most medications induce in vulnerable persons are being critically discussed as a result of European Medicines Agency withdrawing its original official approval. It is premature to promote Integrin beta-3 as a possible diagnostic biomarker of idiosyncratic drug-induced liver injury at this time because of a few clear ambiguities. For idiosyncratic drug-induced liver injury, new biomarkers are ideal, but as a gold standard, they need to be confirmed with high causality grade Rousseau Uclaf Causality Assessment Method based drug-induced liver injury patients. It needs to be explored whether emerging artificial intelligence technologies can effectively promote diagnostic biomarkers in liver damage instances.

Acknowledgement: *The authors are grateful to the Deanship of Scientific Research, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia, for its support for this research work.*

REFERENCES

1. *Akahashi T, Shishido T, Kinoshita D, Watanabe K, Toshima T, Sugai T, et al, (2019).* Cardiac Nuclear High-Mobility Group Box 1 Ameliorates Pathological Cardiac Hypertrophy by Inhibiting DNA Damage Response. JACC Basic Transl Sci. 2019 Apr 29;4(2):234-247. https://doi.org/10.1016/j.jacbts.2018.11.011
2. *Bangaru S, Benhammou JN, & Tabibian JH et al, (2020).* Noninvasive scores for the prediction of esophageal varices and risk stratification in patients with cirrhosis. *World journal of hepatology*, *12*(11), 908–918. https://doi.org/10.4254/wjh.v12.i11.908
3. *Bari Md N., Osman E.H.A., Alfaki M.A. , Ansari Md R. (2024).* Noninvasive proteomic biomarker in disorders of the nonalcoholic fatty liver: A systematic review, The New Armenian Medical Journal, vol.18(2), 60-67; https://doi.org/10.56936/18290825-3.v18.2024-602.
4. *Basra G, Basra S, & Parupudi S, (2011).* Symptoms and signs of acute alcoholic hepatitis. World journal of hepatology, 3(5), 118–120. https://doi.org/10.4254/wjh.v3.i5.118
5. *Contreras-Zentella ML, Hernández-Muñoz R, (2016).* Is Liver Enzyme Release Really Associated with Cell Necrosis Induced by Oxidant Stress? Oxid Med Cell Longev. 2016;2016:3529149. https://doi.org/10.1155/2016/3529149
6. *Huang XJ, Choi YK, Im HS, Yarimaga O, Yoon E, & Kim HS, (2006).* Aspartate Aminotransferase (AST/GOT) and Alanine Aminotransferase (ALT/GPT) Detection Techniques. *Sensors (Basel, Switzerland)*, *6*(7), 756–782. https://doi.org/10.3390/s6070756
7. *Lad A, Breidenbach JD, Su RC, Murray J, Kuang R, Mascarenhas A, (2022).* As We Drink and Breathe: Adverse Health Effects of Microcystins and Other Harmful Algal Bloom Toxins in the Liver, Gut, Lungs and Beyond. *Life (Basel, Switzerland)*, *12*(3), 418. https://doi.org/10.3390/life12030418
8. *Li Q, Wang Y, Ma T, Liu X, Wang B, Wu Z, Lv Y, & Wu R, (2017).* Impact of cigarette smoking on early complications after liver transplantation: A single-center experience and a meta-analysis. *PloS one*, *12*(5), e0178570. https://doi.org/10.1371/journal.pone.0178570
9. *Lim AK, (2020).* Abnormal liver function tests associated with severe rhabdomyolysis. *World journal of gastroenterology*, *26*(10), 1020–1028. https://doi.org/10.3748/wjg.v26.i10.1020
10. *McGill MR, (2016).* The past and present of

serum aminotransferases and the future of liver injury biomarkers. *EXCLI journal*, *15*, 817–828. https://doi.org/10.17179/excli2016-800

11. *Mueller S, Englert S, Seitz HK, Badea RI, Erhardt A, Bozaari B, Beaugrand M, Lupşor-Platon M. (2015)* (Inflammation-adapted liver stiffness values for improved fibrosis staging in patients with hep atitis C virus and alcoholic liver disease. Liver Int. 2015 Dec;35(12):2514-21. doi: 10.1111/liv.12904. Epub 2015 Jul 30. PMID: 26121926.

12. *Noble JM, & Weimer LH, (2014).* Neurologic complications of alcoholism. *Continuum (Minneapolis, Minn.)*, *20*(3 Neurology of Systemic Disease), 624–641. https://doi.org/10.1212/01.CON.0000450970.99322.84

13. *Poyil M.M., Bari M.D.N. (2023)*. Repurposing the drug duloxetine for its antibacterial activity against catheter associated urinary tract infections. The New Armenian Medical Journal. 17(1): 54-62 DOI: https://doi.org/10.56936/18290825-2023.17.54-62

14. *Ranganathan K, & Sivasankar V, (2014).* MicroRNAs - Biology and clinical applications. *Journal of oral and maxillofacial pathology : JOMFP*, *18*(2), 229–234. https://doi.org/10.4103/0973-029X.140762

15. *Sanjay S; Girish C,, (2017).* Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury. Eur J Clin Pharmacol. 2017 Apr;73(4):399-407. https://doi.org/10.1007/s00228-016-2183-1

16. *Schmidt JR, Wilhelm S W, & Boyer GL, (2014).* The fate of microcystins in the environment and challenges for monitoring. *Toxins*, *6*(12), 3354–3387. https://doi.org/10.3390/toxins6123354

17. *Schofield AL, Brown JP, Brown J, Wilczynska A, Bell C, Glaab WE, et al, (2021).* Systems analysis of miRNA biomarkers to inform drug safety. *Archives of toxicology*, *95*(11), 3475–3495. https://doi.org/10.1007/s00204-021-03150-9

18. *Schueller F, Roy S, Vucur M, Trautwein C, Luedde T, & Roderburg C et al, (2018).* The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. *International journal of molecular sciences*, *19*(1), 261. https://doi.org/10.3390/ijms19010261

19. *Senior JR, (2014).* Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. *Drug safety*, *37 Suppl 1*(Suppl 1), S9–S17. https://doi.org/10.1007/s40264-014-0182-7

20. *Sirlin CB, & Reeder SB, (2010).* Magnetic resonance imaging quantification of liver iron. *Magnetic resonance imaging clinics of North America*, *18*(3), 359–ix. https://doi.org/10.1016/j.mric.2010.08.014

21. *Takahashi Y, & Fukusato T, (2014).* Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *World journal of gastroenterology*, *20*(42), 15539–15548. https://doi.org/10.3748/wjg.v20.i42.15539

22. *Tian Z, Liu H, Su X, Fang Z, Dong Z, Yu C, & Luo K et al, (2012).* Role of elevated liver transaminase levels in the diagnosis of liver injury after blunt abdominal trauma. *Experimental and therapeutic medicine*, *4*(2), 255–260. https://doi.org/10.3892/etm.2012.575

23. *Torruellas C, French SW, & Medici V, (2014).* Diagnosis of alcoholic liver disease. *World journal of gastroenterology*, *20*(33), 11684–11699. https://doi.org/10.3748/wjg.v20.i33.11684

24. *Van Waes L, Lieber CS, (1977).* Glutamate dehydrogenase: a reliable marker of liver cell necrosis in the alcoholic. *British medical journal*, *2*(6101), 1508–1510. https://doi.org/10.1136/bmj.2.6101.1508

25. *Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galasl DJ, (2009).* Circulating microRNAs, potential biomarkers for drug-induced liver injury. *Proceedings of the National Academy of Sciences of the United States of America*, *106*(11), 4402–4407. https://doi.org/10.1073/pnas.0813371106

26. *Wazir H., Abid M, Essani B, Saeed H, Khan MA, Nasrullah et al FNU, (2023).* Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. *Cureus*, *15*(12), e49920. https://doi.org/10.7759/cureus.49920

THE NEW ARMENIAN MEDICAL JOURNAL
Volume19 (2025). Issue 3

CONTENTS

4. *Avagyan A.S., Muradyan A.A., Makletsova M.G., Poleshchuk B.B., Zilfyan A.V.*
THE ROLE OF ALIPHATIC POLYAMINES AND A-SYNUCLEIN IN THE FORMATION OF PERIPHERAL MECHANISMS INVOLVED IN THE PARKINSON'S DISEASE INDUCTION

17. *Shuliatnikova O.A., Karakulova Y.V., Batog E.I., Rogoznikov G.I.*
STUDY OF THE COMORBID ASSOCIATION OF INFLAMMATORY PERIODONTAL DISEASES AND PATHOLOGY OF THE NERVOUS SYSTEM

23. *Bari Md.N., Anwar Md., Ansari Md.R., Osman. E.H.A., Alfaki, M.A., Mohammad I.*
A COMPLICATED SITUATION OF DIAGNOSIS OF BIOMARKERS IN ALCOHOLIC LIVER CIRHOSIS INJURY BY ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD

30. *Gavanji S., Bakhtari A., Baghshahi H., Hamami Chamgordani Z., Gavanji J., Sinaei J., Hassani D.*
COMPARING THE ANTI-CANDIDA ALBICANS EFFECT OF ZINGIBER OFFICINALE WITH COMMON ANTIFUNGAL DRUGS

37. *Masnavi E., Hasanzadeh S.*
FREQUENCY OF AMINOGLYCOSIDES RESISTANCE GENES (ANT(4')-IA, APH(3')-IIIA, AAC-(6')-IE-/APH]2) IN STAPHYLOCOCCUS AUREUS ISOLATED FROM SURGICAL AND RESPIRATORY SITE INFECTIONS

44. *Shahsafi M., Madrnia M., Mohajerani H.R., Akbari M.*
EVALUATION OF THE ANTIBACTERIAL ACTIVITY OF CYNARA SCOLYMUS EXTRACT AND ITS WOUND HEALING POTENCY AGAINST MULTIDRUG-RESISTANT *ACINETOBACTER* BAUMANNII, *In vitro* AND *In Vivo* STUDY

57. *Kanannejad Z., Hosseini S.F., Karimpour F., Taylor W.R, Gevorgian L., Ghatee M. A.*
EXPLORING CLIMATIC AND GEOGRAPHICAL DRIVERS OF HEPATITIS B VIRUS SPREAD IN KOHGILUYEH AND BOYER-AHMAD PROVINCE, IRAN

67. *Sametzadeh M., Roghani M., Askarpour S., Shayestezadeh B., Hanafi M.G.*
NON-ENHANCED CT FINDINGS IN PATIENTS SUSPECTED OF ACUTE APPENDICITIS WITH NON-DIAGNOSTIC ULTRASONOGRAPHY

75. *Zharfan A.S., Airlangga P.S., Santoso K.H., Fitriati M.*
PERIOPERATIVE MANAGEMENT OF CESAREAN SECTION IN A PATIENT WITH SEVERE SCOLIOSIS: A CASE REPORT

82. *Mohammadi Arani F., Shirmohammadi M., Tavakol Z., Karami M., Raeisi Shahraki H., Khaledifar A.*
EFFECTIVENESS OF COGNITIVE BEHAVIORAL THERAPY ON SEXUAL SELF-EFFICACY IN REPRODUCTIVE-AGED WOMEN WITH CARDIOVASCULAR DISEASE (A RANDOMIZED CLINICAL TRIAL STUDY)

91. *Maghakyan S.A., Aghajanova E.M., Khachaturyan S.R., Hrantyan A.M., Melkonyan N.R., Aleksanyan A.Y., Barseghyan E.S., Muradyan A.A.*
ASSOCIATION OF PRIMARY HYPERPARATHYROIDISM AND PAPILLARY THYROID CARCINOMA IN A PATIENT WITH BROWN TUMOR AND PARKINSONISM: CASE REPORT

97. *Martirosyan D. A., Muradyan A. A.*
COVID-19 ASSOCIATED INCRUSTING CYSTITIS: A CASE REPORT

102. *Faghihrad H.R., Sheikhbagheri B., Roknabadi M., Shapouri R.*
HERBAL OINTMENT BLEND AND ANTIBACTERIAL ACTIVITY

108. *Fanarjyan R.V., Zakaryan A.V., Kalashyan M.V., Zakaryan A.N.*
ACUTE INTRATUMORAL HEMORRHAGE IN A MENINGOTHELIAL MENINGIOMA: A CASE REPORT OF EMERGENCY RESECTION

112. *Mkrtchyan R.A., Ghardyan G.K., Abrahamyan L.R., Karalyan N.Yu., Abrahamyan S.H., Abrahamyan R.A.*
SIRENOMELIA: A UNIQUE CONGENITAL ANOMALY (CLINICAL CASE)

THE NEW ARMENIAN MEDICAL JOURNAL

Volume19 (2025). Issue 3

The Journal is founded by
Yerevan State Medical
University after M. Heratsi.

Rector of YSMU

Armen A. Muradyan

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU
(+37493 588697 Editor-in-Chief
Fax: (+37410) 582532
E-mail:namj.ysmu@gmail.com, ysmiu@mail.ru
URL:http//www.ysmu.am

Our journal is registered in the databases of Scopus, EBSCO and Thomson Reuters (in the registration process)

SCOPUS *EBSCO*
REUTERS

Copy editor: Kristina D Matevosyan

LLC Print in "Monoprint" LLC

Director: Armen Armenakyan
Andraniks St., 96/8 Bulding
Yerevan, 0064, Armenia
Phone: (+37491) 40 25 86
E-mail: monoprint1@mail.ru